Synlogic Initiates Phase 1 Study of SYNB1353 for the Treatment of Homocystinuria (HCU)
July 12, 2022 07:00 ET
|
Synlogic, Inc.
Expected data in H2 2022 brings Synlogic to three clinical readouts this year Third candidate in less than two years to enter the clinic; Reflects productivity of Synthetic Biotic platform ...
Synlogic Announces Appointment of General Counsel and Corporate Secretary
June 29, 2022 07:00 ET
|
Synlogic, Inc.
CAMBRIDGE, Mass., June 29, 2022 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage biotechnology company developing medicines for metabolic and immunological diseases through its...
Synlogic Announces Fourth Quarter and Full Year 2021 Conference Call and Webcast
March 10, 2022 07:00 ET
|
Synlogic, Inc.
CAMBRIDGE, Mass., March 10, 2022 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage biotechnology company developing medicines for metabolic and immunological diseases through its...
Synlogic Announces Appointment of Michael Jensen as Chief Financial Officer
March 03, 2022 07:00 ET
|
Synlogic, Inc.
CAMBRIDGE, Mass., March 03, 2022 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage biotechnology company developing medicines for metabolic and immunological diseases through its...
Synlogic To Present at Upcoming Investor and Industry Conferences
February 24, 2022 07:00 ET
|
Synlogic, Inc.
CAMBRIDGE, Mass., Feb. 24, 2022 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage biotechnology company developing medicines for metabolic and immunological diseases through its...
Synlogic To Present at Upcoming Investor and Industry Conferences
February 08, 2022 07:00 ET
|
Synlogic, Inc.
CAMBRIDGE, Mass., Feb. 08, 2022 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage biotechnology company developing medicines for metabolic and immunological diseases through its...
Synlogic Announces Progress Toward 2022 Clinical Milestones and Participation at Upcoming Investor Conferences
January 06, 2022 07:00 ET
|
Synlogic, Inc.
- On track to initiate Phase 3 for treatment of phenylketonuria (PKU) in H2 2022 - - Additional milestones include multiple clinical read-outs across programs including enteric hyperoxaluria and...